Compare iShares Core S&P 500 ETF (IVV) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Core S&P 500 ETF trades at $779.81 (market cap $897.20B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: iShares Core S&P 500 ETF is far larger — about 7× Vertex Pharmaceuticals Incorporated's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| IVV | VRTX | |
|---|---|---|
Market Cap | $897.20B | $127.55B |
Volume | 4,580,672 | 1,487,944 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $557.96 |
52-Week Low | $634.93 | $407.37 |
Typical Hold Time | 46 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $780.6, down 0.25% on the day. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions near-term. The ETF benefits from diversified exposure to large-cap US equities, with recent news highlighting strong corporate earnings growth expectations of 35% for 2026. Market sentiment remains mixed amid concerns about valuation and profit growth normalization.
Outlook remains cautiously optimistic given the S&P 500's historical bullish seasonal patterns and strong institutional support. Key risks include elevated Treasury yields, concentration in top holdings, and potential earnings growth deceleration to 15% in 2027. The ETF's low-cost structure and broad market exposure provide defensive characteristics during market volatility.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
